Fecal iron quantification in a randomized controlled trial of *Lactiplantibacillus plantarum* ATCC 202195 in newborns in Dhaka, Bangladesh

Afreen Z. Khan[a, b], Anjan K. Roy[c], Huma Qamar[a], Lisa G. Pell[a], Karen M. O'Callaghan[d], Shafiqul A. Sarker[c], Abdullah A. Mahmud[c,1], Rashidul Haque[c], Sharmin Akter[c], Shamima Sultana[c], Daniel E. Roth[a, b, e,*], Rubhana Raqib[c*].

[a]Centre for Global Child Health and SickKids Research Institute, Hospital for Sick Children, Toronto, Canada.

[b]Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

[c]International Centre for Diarrhoeal Disease Research (icddr,b), Dhaka, Bangladesh.

[d]Department of Nutritional Sciences, King's College London, London, United Kingdom.

[e]Department of Paediatrics, Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada.

[1]Current Affiliation: Shield Pharmaceuticals Corp. Ronkonkoma, NY 11779, USA

* Contributed equally as co-senior authors.

Corresponding author: Daniel E. Roth, Department of Paediatrics, The Hospital for Sick Children and University of Toronto, 686 Bay Street, Toronto, ON, M5G 0A4, daniel.roth@sickkids.ca

List of Abbreviations

AAS   Atomic absorption spectrometry

ATCC   American type culture collection

CBL   Clinical Biochemistry Lab

CI   Confidence interval

EBF   Exclusively breastfed/Exclusive breastfeeding

FOS   Fructooligosaccharide

icddr,b   International Centre for Diarrhoeal Disease Research, Bangladesh

ID   Iron deficiency

IDA   Iron deficiency anemia

IP   Investigational product

INTL   Immunobiology, Nutrition and Toxicology Laboratory (INTL)

LMIC   Low- or middle-income country

LP1   *Lactiplantibacillus plantarum* ATCC 202195 without FOS for 1 day

LP1+FOS   *Lactiplantibacillus plantarum* ATCC 202195 with FOS for 1 day

LP202195   *Lactiplantibacillus plantarum* ATCC 202195

LP7   *Lactiplantibacillus plantarum* ATCC 202195 without FOS for 7 days

LP7+FOS   *Lactiplantibacillus plantarum* ATCC 202195 with FOS for 7 days

MCHTI   Maternal and Child Health Training Institute

MFSTC   Mohammadpur Fertility Services and Training Centre

SD   Standard deviation

SGA   Small for gestational age

WHO   World Health Organization

Abstract

Background: Probiotics may enhance host iron bioavailability, offering a strategy to address iron

deficiency. Fecal iron may be a useful non-invasive biomarker of such effects in infants.

Objective: To examine the use of fecal iron quantification in a randomized placebo-controlled

trial (RCT) of neonatal administration of *Lactiplantibacillus plantarum* ATCC 202195

(LP202195), with or without fructooligosaccharide (FOS), in Dhaka, Bangladesh.

Methods: Fecal iron quantification using atomic absorption spectrometry (AAS) was optimized

using standards and reference materials, and pilot-tested using pooled stool aliquots (n=32) from

an observational cohort of young infants in Bangladesh (aged 0-64 days). The optimized AAS

assay was then applied to individual stool samples collected at 14 days of age (n=307) in a RCT

in which newborns aged 0-4 days were randomly allocated to one of five groups: placebo, 1- or

7-day regimens of LP202195, with or without FOS. Serum ferritin was measured at 2 months

postnatal age (n=251). Effects of the 1- and 7-day LP202195 regimens were estimated using

linear regression and expressed as mean percent differences relative to placebo, with 95%

confidence intervals (95%CI).

Results: The optimized AAS fecal iron assay had acceptable accuracy (91-99%), precision

(within- and between-run coefficients of variation <10%), and recovery (93-112%), with a

reportable range of 0.2 to 80 mg Fe per 100 g dry stool. In pooled samples from the

observational cohort, fecal iron varied with age and feeding status. In the RCT, fecal iron

concentrations did not significantly differ following1-day (% difference=9.8%, 95%CI: -19%,

49%; P=0.54) or 7-days (% difference= -6.1%, 95%CI: -31%, 28%; P=0.69) of LP202195

administration, versus placebo (geometric mean concentration=4.3mg Fe/100g dry stool

(95%CI:3.3, 5.6); n=53). Inferences were unchanged when groups were disaggregated by FOS

co-administration (P>0.05 for all). Similarly, there were no effects of LP202195 on serum

ferritin at 2 months of age (P>0.05 for all).

Conclusions: Fecal iron quantification by AAS was valid and feasibly implemented in a trial of

neonatal administration of *Lactiplantibacillus plantarum* ATCC 202195. However, the assay is

resource-intensive and may not be more informative than conventional measures of iron status

when studying the effects of probiotics/synbiotics on iron bioavailability.

Clinical Trial Registry: ClinicalTrials.gov identifier: NCT05180201

Keywords: iron; probiotics; synbiotic; *L. plantarum*; microbiota; ferritin; iron deficiency; fecal

iron; iron absorption; iron status

Introduction

Iron deficiency (ID) is common during early childhood and can have irreversible adverse effects on neurodevelopment[1, 2]. Daily oral iron supplementation reduces the risk of ID, anemia, and iron deficiency anemia in children aged 4 to 23 months[3]. However, iron stores in term, exclusively breastfed infants are generally assumed to be sufficient until 4 to 6 months of age[4-6]; for this reason, the World Health Organization (WHO) only recommends routine iron supplementation for infants aged 6 months and older in low- and middle-income countries (LMICs) where there is a high prevalence of ID and anemia[7]. WHO also recommends a daily intake of 30-60mg elemental iron along with 0.4mg folic acid in pregnancy, starting soon after conception[8]. Yet, many infants in LMICs may be iron deficient at an earlier age (< 6 months) due to the greater risk of preterm birth and low birthweight, which are associated with lower iron stores at birth[9]. Additionally, iron absorption is more likely to be impaired in populations living in LMICs due to a higher prevalence of infection and chronic inflammation[10, 11], thereby contributing to the risk of ID. Since most intestinal bacteria rely on iron for survival and virulence [12], there is competition between intestinal microbes and their human host for iron in the gastrointestinal tract, whereby excess intraluminal iron may promote the proliferation of pathogenic bacteria rather than benefit the host[13].

While iron supplementation and fortification strategies have shown benefits in reducing the prevalence of ID and anemia in infants and young children[3, 14], the safety of iron-containing interventions has been questioned in some LMIC settings with high rates of malaria and/or other infections, where clinical trials have linked exogenous iron to an increased risk of serious adverse events including deaths and hospital admissions[15], and bloody diarrhea[16]. Iron interventions may negatively impact the gut microbiota composition by increasing the abundance

of potentially pathogenic bacteria and decreasing the abundance of commensal bacteria, which

may contribute to intestinal inflammation[13, 17]. Alternative interventions that safely improve

iron status are therefore of interest and may be particularly applicable in early infancy before the

age when routine iron supplementation is recommended. Lactobacilli probiotics are iron-

independent and have the potential to improve iron absorption in the human intestine[18-20]

through multiple pathways including alteration of gut microbiota composition[19], increases in

lactic acid and short-chain fatty acids that may lower intestinal pH[21, 22], and the production of

other metabolites that promote iron solubility[23]. The co-administration of iron and lactobacilli-

containing probiotic regimens has been shown to improve iron absorption in animal models[24]

and in human females of reproductive age[18, 25, 26], but such benefits have not been observed

to date in pediatric populations[27, 28]. Little is known about the effect of probiotic

administration alone on gastrointestinal iron absorption without co-administration of an

exogenous iron source, and no studies have explored the effect of probiotic administration in

early infancy on iron status or markers of iron absorption or excretion.

Fecal iron concentration is a non-invasive measure of ingested unabsorbed iron, but is not a

direct marker of iron status or iron absorption. However, fecal iron may be valuable in studies of

microbiome-iron interactions because the same stool samples collected for microbiome analyses

may be used for iron quantification, potentially alleviating the need for blood collection or use of

direct yet more expensive methods such as stable isotope administration[29]. While several

techniques for fecal iron quantification have been described in the literature, none are routinely

used in the context of microbiome or probiotic research[29]. In the present study, we first

optimized and validated an atomic absorption spectrometry (AAS) method for fecal iron

quantification in stool samples from a cohort of infants in Bangladesh. Then, in a sub-study of a

randomized placebo-controlled trial (RCT) of *Lactiplantibacillus plantarum* ATCC 202195

(LP202195)[30], we applied this method to examine if LP202195 with and/or without

fructooligosaccharide (FOS), for 1- or 7-days, affects stool iron content at 14 days postnatal age

and serum ferritin at 60-days postnatal age in young infants in Dhaka, Bangladesh. In the context

of the RCT, whereby average prenatal endowment of iron stores and postnatal iron intake were

assumed to be similar across the intervention groups, we expected that a relatively lower stool

iron concentration in infants in the intervention group compared to placebo would indicate

reduced intraluminal excess iron and lower stool iron losses, thereby serving as an indirect

indicator of greater fractional iron absorption. We further anticipated that an increase in iron

absorption following probiotic intervention would manifest as a greater mean ferritin

concentration in the intervention group relative to placebo at 2 months of age.

Methods

Part A: Fecal iron assay optimization and validation

Stool samples for assay optimization were randomly selected from infants enrolled in the

SEPSiS observational cohort study (ClinicalTrials.gov ID: NCT04012190) for which

recruitment, enrollment and stool collection procedures have been previously described (Section

A in Supplementary Material)[31]. Samples collected from 0 to 60 days of age (n=130) were

pooled and divided into 1-2 g aliquots. Reference materials and spiked samples were also used in

optimization procedures (Table S1 in Supplementary Material).

The sample processing and AAS method was adapted from Pizarro *et al.*[32] and Fairweather-

Tait *et al*[33]. Aliquots were placed in a freeze dryer for 3-4 days, following which the weight of

the dry stool was determined. Specimens were transferred into re-usable crucibles which were

washed thoroughly between uses using chromic acid followed by nitric acid. The crucibles were

organized inside a muffle furnace and specimens ashed at increasing temperatures as follows:

100°C for 1 hour, 200°C for 1 hour, 500°C for 2 hours and 600°C for 2 hours. The ashing

procedure was repeated every day for up to 3 days, and considered complete when the sample

was entirely white (i.e., lacking black residue). Spiked stool samples, rice flour and turmeric

powder were lyophilized and ashed in a similar manner. Each ashed sample was reconstituted in

2mL of 0.2N hydrochloric acid (HCl), then further diluted and aspirated into the flame of the

ASC-7000 Atomic Absorption Autosampler (Shimadzu, Maryland, USA). Initial dilutions were

5-fold, but increased to 10-, 20-, or 40-fold until an absorbance value in the reportable range was

obtained. Absorbances were read using a wavelength range of 248.3nm and iron concentrations

were determined using a standard curve generated using five dilutions of a stock solution of

known iron concentration, with final concentrations ranging from 0.4 to 4.0mg/L (Figure S1).

Exploratory analyses indicated that results were not acceptably reproduced when specimen

weights were below 0.25g (dry weight of stool); also, it was not expected that dry weights

greater than ~0.3g would be readily available in future studies using individual infant stool

aliquots. Therefore, we decided to perform all subsequent assays using at least 0.3g lyophilized

stool.

The assay performance characteristics included lower limit of quantification (LLOQ), lower limit

of detection (LOD), precision expressed as coefficients of variation (CV%), accuracy

(percentage error from the known standard) and iron recovery (Section B in Supplementary

Material).

A pilot study was conducted using an additional set of 158 stool samples from 123 infants

(pooled into 32 samples) from the SEPSiS observational cohort. Samples were selected using a

stratified approach with 4 variables (details in Supplementary Material, Section C):

i.   Age (enrolment, and days 14 and 60 +/- 7-days for each age time point)

ii.   Infant feeding pattern (exclusive or predominant breastfeeding, partial breastfeeding, and

127   no breastfeeding)

iii.   Sex (Male vs. Female)

iv.   Neonatal nutritional status (Yes or No for underweight)

Fecal iron quantification was performed as described above and expressed as mg of iron/100g

dry weight of stool for each pool. Pools were combined for analysis based on shared

characteristics (Supplementary Table S5), and iron concentration was expressed as mean

(standard deviation) with 95% Confidence Intervals (95% CI).

Part B: Fecal iron quantification in a randomized controlled trial

Study design and participants

This study was nested within a randomized, placebo-controlled trial of neonatal oral

administration of LP202195 with or without FOS, for 1- or 7-days (ClinicalTrials.gov ID:

NCT05180201), referred to below as the SEPSiS LP trial, for which recruitment, eligibility

screening, and enrollment procedures have been previously described (Section A in

Supplementary Material)[30]. In brief, infants were recruited, screened, and enrolled at two

government hospitals in Dhaka, Bangladesh: Maternal and Child Health Training Institute

(MCHTI) and Mohammadpur Fertility Services and Training Centre (MFSTC). Participants

were randomly assigned to one of five intervention groups: placebo; LP202195 without FOS for

1 day (LP1); LP202195 with FOS for 1 day (LP1+FOS); LP202195 without FOS for 7 days

(LP7); or LP202195 with FOS for 7 days (LP7+FOS). Infants were eligible to participate in the

primary trial if they were: delivered at MCHTI or MFSTC; 0 to 4 days of age (day of birth was

defined as day 0); weighed ≥1500g at birth; orally feeding at the time of eligibility assessment;

and, their caregiver intended to reside within the study catchment area until the infant was ≥60

days postnatal age. To be eligible for inclusion in this nested sub-study, SEPSiS LP trial

participants (infants) were required to have a stored stool sample aliquot collected at

approximately 14 days postnatal age timepoint (although eligible samples were collected up to 4

weeks of age) and/or a stored blood sample aliquot collected as scheduled for the 60-day visit.

The outcomes in this sub-study, stool iron and serum ferritin, were both specified as secondary

outcomes in the SEPSiS LP trial protocol. Stool iron was quantified in samples collected from

the first 307 infants enrolled in the SEPSiS LP trial for whom at least 2g of a day 14 stool sample

was available for stool iron analysis.

Intervention

Active investigational product (IP) vials consisted of either 10^9 colony forming units of

LP202195 with 150 mg FOS and 100 mg of maltodextrin (synbiotic regimen), or 10^9 colony

forming units of LP202195 and 250 mg of maltodextrin only (probiotic regimen). Placebo-

containing IP vials contained 250 mg of maltodextrin. IPs were preferentially reconstituted in

3mL of human milk (hand-expressed from mother); alternatively, 3mL of sterile water or a

mixture of water and human milk (total 3 mL) were also permitted. IP was orally administered to

infants by study personnel and efforts were made to administer the IP once per day for seven

consecutive days up to a maximum of seven doses per participant between 0-21 days of age[30].

Data and specimen collection

All data were collected in the SEPSIS LP trial during hospital/clinic and home visits, via

standard data collection forms and clinical measurements, using an electronic data capture

system[30]. Study personnel used standard questionnaires at enrollment and/or hospital records

to collect information related to maternal age at delivery, gestational age at delivery, mode of

delivery, gravidity, birthweight, infant sex, maternal education, maternal occupation, enrollment

site and asset index. Infant feeding status was defined using feeding-related data collected up to

the day 14 study visit. Asset index of the participants was based on infants enrolled in both the

SEPSiS LP trial (including infants in this sub-study) as well as the linked SEPSiS observational

cohort. Infant stool samples were routinely collected at enrollment (postnatal days 0-4) and on

postnatal days 4, 5 or 7 (randomly assigned), 10, 14, 21, 28, 42, 60, 90, and 180 (rescheduled

when necessary)[30]. The 14-day postnatal age sample was selected for stool iron assessment as

it was expected that most infants would have completed the probiotic/synbiotic or placebo

intervention regimens prior to this age. All stool samples were collected by trained study

personnel from a sanitized plastic sheet where they were homogenized, aliquoted, placed in the

vapour phase of liquid nitrogen within 20 minutes of defecation, and transported to the

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) for storage at ≤-70°C

until analysis.

Venous blood samples were collected at the postnatal day 60 visit (or if necessary, rescheduled

to a later date up to day 180 of age), and processed to serum at MCHTI or MFSTC[30], before

transfer to icddr,b for storage at <-70C until analysis.

Fecal iron quantification

The dry weight of each stool sample was recorded following sample processing as described for optimization and validation (Part A). Fecal iron concentration was measured using the AAS assay in the Immunobiology, Nutrition and Toxicology Laboratory (INTL) at icddr,b, as described above (Part A). For stool samples with absorbances below the lower limit of quantification (LLOQ) of 0.2mg per 100g dry stool, values were imputed at one-half the LLOQ (i.e., 0.1 mg per 100 g dry stool) (Section B Supplementary Material).

Serum ferritin and C-reactive protein (CRP)

Serum ferritin was quantified using an automated chemiluminescence assay kits (007P65030, Abbott) on an Abbott Alinity analyzer. The between-and within-assay CVs were 5.82% and 2.78%, respectively, with a reportable range of 1.98 – 167.56ng/ml and an LLOQ of 1.98ng/ml. Serum CRP was measured using the high-sensitivity CRP assay on the Beckman Coulter autoanalyzer (OSR6199); the LLOQ was 0.08 mg/L and values below the LLOQ were imputed at 1/2 LLOQ (0.04 mg/L).

Statistical analysis

The distributions of variables across intervention arms were visualized using histograms, k-density plots, and boxplots, as appropriate. Continuous normally and non-normally distributed variables were summarized using means (with standard deviations, SD) or medians (with 25th and 75th percentiles), respectively. Categorical variables were described as the frequencies and proportions in each category. Study outcomes (i.e., stool iron, serum ferritin, serum CRP) were natural log (ln)-transformed to approximate a normal distribution for regression analyses.

Average biomarker concentrations in each of the placebo and intervention groups were expressed

as geometric means with 95% confidence intervals (CI).

Primary analyses were conducted using an intention-to-treat (ITT) approach, whereby

participants who received the LP1 or LP1+FOS intervention were combined to create a single

LP1 intervention group. Similarly, participants who received LP7 or LP7+FOS were combined

to create a single LP7 intervention group. To examine the effect of probiotic administration (as

1- or 7-day regimens) on stool iron content and iron status, unadjusted linear regression models

were fitted using intervention groups as the categorical exposure variable and the ln-transformed

biomarker of interest as the continuous outcome measure. Effect estimates were back-

transformed and reported as mean percent differences and 95%CIs for each intervention group

relative to placebo. In further analyses, the combined intervention groups (1- or 7-day regimens)

were disaggregated to examine the effect of each probiotic regimen (i.e., with or without FOS)

relative to placebo, using the same modeling approach as in the primary analyses.

In supplementary analyses, we conducted subgroup analyses stratified by selected infant

characteristics (sex, breastfeeding pattern up to 14 days of age, mode of delivery, and

birthweight). We also examined these selected infant characteristics as effect-modifiers of the

intervention effect on the primary outcome (stool iron concentration) by introducing interactions

of the hypothesized modifiers with intervention group in the linear regression model,

acknowledging these were exploratory analyses given the low sample sizes within each stratum.

For this analysis, breastfeeding pattern up to 14 days postnatal age was dichotomized as

exclusively breastfed (EBF) and not EBF, as most infants during the first 2 weeks after delivery

received only human milk, resulting in a very small sample size in the other feeding-related sub-

groups (e.g., partially, predominantly, or not breastfed). In a further supplementary analysis,

separate unadjusted linear regression models were used to examine associations between the

primary outcome (stool iron concentration) and each of the following covariates of interest:

infant sex, breastfeeding pattern up to 14 days of age, mode of delivery and birthweight. The

purpose of this additional exploratory analysis was to examine if the outcome measure captured

meaningful between-infant variation in stool iron content and thereby corroborated the findings

of the pilot testing of pooled samples (Part A). CRP was previously shown to be similar in the

probiotic/synbiotic versus placebo groups in the primary report of the LP trial[30]; however, to

address the potential contribution of systemic inflammation to increases in ferritin, we analyzed

ln-transformed serum CRP overall and across intervention groups among infants included in this

sub-study.

Results

Part A: Fecal iron assay optimization and validation

The optimized assay had a LLOQ of 0.2mg Fe/100g stool and LOD of 0.02 mg Fe/L (Section B

in Supplementary Material). Accuracy using iron standards was 91 to 99% (Supplementary

Table S2), and intra-run precision and inter-run coefficients of variation (CV%) were below 10%

using reference materials and pooled stool samples (Supplementary Table S3). Recovery of iron

from stool samples ranged from 93 to 112%, whereas recoveries for rice flour and turmeric

powder were 98% and 99%, respectively (Supplementary Table S4).

Among 32 pools of infant stool samples, iron concentrations ranged from 0.1 to 12.35mg

Fe/100g dry stool (Figure 1). Stool iron concentrations were generally higher at enrolment (0-4

days of age) than at later ages, but differences between samples collected at 10-18 days and 56-

64 days of age were minimal (Supplementary Figure S2). Stool iron concentrations were lower

in pools from infants who were exclusively or predominantly breastfed versus those partially

breastfed (or who had not received breast milk) at postnatal age 0 to 4 days (Supplementary

Figure S3a) and at 2 weeks and 2 months old (Supplementary Figure S3b). Stool iron

concentration did not notably vary by sex (Supplementary Figure S4) nor neonatal underweight

status (Supplementary Figure S5).

Part B: Fecal iron quantification in a randomized controlled trial

Among 519 infants enrolled in the SEPSiS LP trial, 395 (76%) infants were included in this sub-

study: 145 infants had only a day-14 stool sample, 88 infants had only a day-60 serum sample

(actual sample collection ranged from day 60 to 194, whereby ~91% of samples were collected

by 3 months of age) and 162 infants had both a day-14 stool sample and a day-60 serum sample.

In total, 307 participants contributed a stool iron measurement and 251 participants contributed a

serum ferritin measurement (Figure 2). The actual timing of collection of stool samples ranged

from 13 to 27 days postnatal age, with 93% collected from days 14 to 17 inclusive. Baseline

characteristics were generally similar across the intervention groups (Table 1). No infants had a

diarrheal event during the IP administration period and no infants were reported to have received

any iron supplements during the first two weeks postnatal age. Nearly all infants (99%) received

all 7 doses of their assigned intervention before the 14-day stool collection.

Table 1. Participant characteristics, by intervention group (n=307)[1]

Characteristics	Placebo (n= 53)	LP1 (n= 132)	LP7 (n= 122)
Maternal age at delivery (years), median (25th, 75th)	23 (21, 27)	23 (20, 27)	23 (20, 28)
Gestational age at delivery (weeks), median (25th, 75th)[2]	40 (38, 41)	39 (38, 40)	39 (38, 40)
Mode of delivery, n (%)			
Vaginal	29 (55)	62 (47)	59 (48)
C-section	24 (45)	70 (53)	63 (52)
Gravidity (n), median (25th, 75th)	2 (1, 3)	2 (1, 3)	2 (1, 2)
Birthweight (g), mean ± SD	2930 ± 338	2927 ± 374	2894 ± 344
Infant sex, n (%)			
Male	28 (53)	80 (61)	57 (47)
Female	25 (47)	52 (39)	65 (53)
Breastfeeding status up to age 14 days, n (%)[3]			
EBF	30 (57)	97 (73)	99 (81)
Predominant BF	15 (28)	21 (16)	15 (12)
Partial BF	7 (13)	14 (11)	7 (5.7)
No BF	1 (1.9)	0 (0)	1 (0.82)
Maternal education			
None	2 (3.8)	5 (3.8)	10 (8.2)
Primary incomplete	7 (13)	27 (20)	16 (13)
Primary complete	3 (5.7)	15 (11)	12 (9.8)
Secondary incomplete	23 (43)	36 (27)	38 (31)
Secondary complete or higher	18 (34)	49 (37)	46 (38)
Maternal occupation			
Work inside home	50 (94)	123 (93)	116 (95)
Work outside home	3 (5.7)	9 (6.8)	6 (4.9)
Enrollment site			
MCHTI	15 (28)	39 (30)	39 (32)
MFSTC	38 (72)	93 (70)	83 (68)
Asset index quintile, n (%)			
1 (lowest)	13 (25)	29 (22)	24 (20)
2	12 (23)	27 (20)	23 (19)
3	8 (15)	33 (25)	32 (26)
4	8 (15)	24 (18)	21 (17)
5 (highest)	12 (23)	19 (14)	22 (18)

[1] Only infants who contributed stool iron content data (n=307), the study primary outcome, are reflected in this table.
[2] Due to missing gestational age data, n=51, n=131, and n=120 in placebo, LP1 and LP7 groups, respectively.
[3] Breastfeeding pattern was derived using the infant's breastfeeding status up to and including the 14-day stool collection visit, which may have occurred up to 21 days of age.
SD, Standard Deviation; EBF, Exclusively breastfed; BF, Breastfed; MCHTI, Maternal Child Health Training Institute; MFSTC, Mohammadpur Fertility Services and Training Centre

Among 307 participants with a fecal iron measurement in a day-14 stool sample (range: 0.1 to

95.6 mg Fe/100g dry stool), there was no effect of the 1- or 7-day regimens of LP202195

compared to the placebo group on fecal iron content (Table 2; Figure 3A). Among 251

participants with serum ferritin measured in a day-60 serum sample (range: 9.6 to 1219 ng/ml),

there was no effect of 1- or 7-day regimens of LP202195 on serum ferritin concentrations at 2

months of age (Table 2; Figure 4). Inferences were unchanged in disaggregated analysis of

groups based on FOS co-administration (i.e., with or without FOS), such that there were no

effects of the intervention on either day-14 stool iron or day-60 serum ferritin concentrations in

any intervention group compared to placebo (Table S6). Serum CRP was generally very low

(median: 0.4 mg/L; 25th and 75th percentiles: 0.2 and 0.9 mg/L; n=251 infants). Only 10/251

infants (4%) had CRP values above 5 mg/L, and CRP did not differ across intervention groups

(Supplemental Figure S6); therefore, no further analyses were conducted to consider effects of

inflammation on between-group comparisons of serum ferritin.

Table 2. Effect of 1- and 7-day regimens of LP202195 (with and without FOS) on stool iron and serum ferritin concentrations[1]

	Placebo		1-Day Intervention			7-Day Intervention		
	n	Geometric Mean (95% CI)	n	% Difference (95% CI)	*p*	n	% Difference (95% CI)	*p*
Stool Iron Concentration at 14 days of age (mg Fe/100g dry stool)	53	4.3 (3.3, 5.6)	132	9.8 (-19, 49)	0.54	122	-6.1 (-31, 28)	0.69
Serum Ferritin Concentration at 60 days of age (ng/mL)	55	189 (155, 232)	99	2.4 (-22, 35)	0.86	97	1 (-23, 33)	0.94

[1] Effect estimates are reported as % mean differences (with 95% CI) relative to placebo, estimated using unadjusted linear regression models with intervention group as the categorial exposure variable.

283 There was no significant modification of the effects of the 1- or 7-day regimen of LP202195,

284 with and without FOS, on infant stool iron concentration at 14 days postnatal age, in analyses in

285 subgroups of participants stratified by sex, breastfeeding status, mode of delivery, and

286 birthweight, and none of these factors significantly modified the intervention effect (Table 3).

Table 3. Effect of LP202195, with and without FOS, for 1- or 7-days, relative to placebo, on infant stool iron concentration at 14-days, by sex, breastfeeding status, mode of delivery or birthweight strata[1, 2, 3,]

		Placebo	1- Day Intervention Group			7-Day Intervention Group		
	n	Geometric Mean (95% CI)	n	% Difference (95% CI)	p^2	n	% Difference (95% CI)	p^2
Sex								
Male	28	3.8 (2.8, 5.3)	80	25 (-16, 86)		57	14 (-25, 73)	
Female	25	4.8 (3.1, 7.5)	52	-5.6 (-41, 52)	0.37	65	-23 (-51, 22)	0.21
Breastfeeding status								
EBF	30	4.3 (3.2, 5.8)	97	-6.5 (-33, 31)		99	-6.7 (-34, 31)	
Not EBF	23	4.3 (2.6, 6.9)	35	71 (-10, 223)	0.06	23	-4.8 (-53, 92)	0.95
Mode of delivery								
Vaginal	29	3.9 (2.9, 5.1)	62	7.4 (-31, 67)		59	-3.2 (-38, 51)	
C-Section	24	4.8 (3, 7.9)	70	8.3 (-29, 65)	0.98	63	-11 (-42, 36)	0.78
Birthweight[4]								
Normal birthweight	49	4.1 (3.1, 5.5)	114	15 (-16, 57)		103	-4.5 (-31, 32)	
Low birthweight	4	6.3 (3.6, 11)	18	-31 (-78, 123)	0.36	19	-31 (-78, 121)	0.55

[1]Effect estimates were calculated from unadjusted linear regression models, with placebo as the reference group.
[2]Point estimates and 95% CIs are from separate regression models for each subgroup of a covariate.
[3]P-values were from a single model for each covariate, used to test the interaction effect, whereby males, EBF, vaginal delivery and normal birthweight (≥2500g) were reference groups. P<0.05 was considered a statistically significant interaction effect.
[4]Normal birthweight was defined as a weight of ≥2500g measured at birth, and low birthweight was defined as a weight of <2500g measured at birth.
EBF, Exclusively breastfed

287   In supplementary analyses, stool iron concentrations were significantly lower among infants who

288   were exclusively breastfed compared to those who were not (Table 4; Figures 3B and 3C), but

289   stool iron concentrations did not vary significantly by sex, mode of delivery, or birthweight in

290   unadjusted analyses (Table 4).

Table 4. Associations of perinatal factors with stool iron concentration at 14 days of age

Factor	$N_A;N_B$[1]	% Difference (95% CI)	p
Male (vs Female)	165;142	6.8 (-14, 32)	0.55
EBF (vs not EBF)	226;81	-23 (-40, -2.7)	0.03
Vaginal delivery (vs C-section)	150;157	-18 (-34, 1.4)	0.066
Normal birthweight (vs low birthweight)	266;41	-3.8 (-30, 32)	0.81

[1]N_A: sample size in primary sub-group; N_B: sample size in the reference subgroup (identified in parentheses in column to the left)

EBF, Exclusively breastfed

Given the negative association between EBF and stool iron content, and acknowledging that EBF

was not evenly distributed across the intervention groups, we conducted a covariate-adjusted

model for the primary outcome with adjustment for EBF status at 14 days of age; this post-hoc

analysis did not change the primary inferences such that there was no effect of the intervention

on fecal iron following 1 day (% difference=15%, 95%CI: -15%, 56%; P=0.37) or 7 days (%

difference=0.22%, 95%CI: -27%, 37%; P=0.99) of probiotic and/or synbiotic administration.

Discussion

We optimized an optimized AAS assay for stool iron quantification, which had acceptable

sensitivity, accuracy, precision, and recovery, and was feasibly applied to the determination of

fecal iron concentration in samples from young infants in a cohort study and RCT in Bangladesh.

We did not find evidence of an effect of LP202195, when administered with and/or without FOS

for 1- or 7-days, on stool iron concentration at 14 days, and similarly there was no evidence of an

effect on serum ferritin at 60 days postnatal age. Although the small sample size and early age

timepoints at which samples were collected are important limitations of this trial sub-study, we

demonstrated the practical considerations and challenges of developing and implementing a stool

iron quantification assay for application in the context of a randomized trial of a

probiotic/synbiotic in early infancy.

As an indirect biomarker of relative iron bioavailability, fecal iron has the advantage of being

measurable in stool samples collected for other purposes in the context of microbiome studies

and probiotic/synbiotic trials, in contrast to iron status biomarkers (which do not reflect intestinal

iron dynamics, and require invasive blood sampling) and the relative complexity of stable-

isotope studies[34]. However, analytical methods to measure stool iron are not widely used and

there is no standard method in the literature, particularly for pediatric cohorts in which low stool

sample volumes may fail to meet typical assay requirements[29]. Therefore, following

development and validation of an AAS assay for infant stool aliquots by adapting previously

published protocols, and achieving acceptable performance after assay optimization, the method

was considered suitable for application in the context of a RCT.

The observed mean and range of stool iron concentration at 14 days postnatal age in the present

study (4.3 mg Fe/100g dry stool, range of 0.1 to 95.6mg Fe/100g dry stool) were consistent with

results previously reported for infants of similar ages in Chile and England[32, 33]. For example,

Pizarro *et al*. reported that infants 3 to 15 months old in Chile had stool iron levels of 8.9mg

Fe/100g stool when fed non-iron fortified formula and 27mg Fe/100g stool when iron-fortified

formula was consumed[32]. Similarly, newborn infants aged 7 to 10 days in England who

received iron-fortified formula had an average stool iron concentration of 9.2mg Fe/100g

stool[33]. Numerous factors are known to affect stool iron concentration including diet, intestinal

microbiota, inflammation, and intestinal sloughing and bleeding[29, 35], which may explain the

wide range of stool iron concentrations among infants in the present study. Corroborating the

preliminary findings using pooled samples in the pilot study, stool iron concentrations were

significantly lower among infants in the RCT who were EBF within the first 14 days compared

to those who were not EBF. This finding may be explained by the iron present in fortified infant

formula, which is at higher concentrations but less bioavailable than the iron in human milk[4,

6]. When interaction effects were tested, none of the factors included in the analysis, including

breastfeeding status, significantly modified the intervention effect, although we recognize the

small sample size of the non-EBF group was a major limitation of the subgroup analyses.

Nonetheless, the negative association between breastfeeding status and stool iron was in the

direction expected, thereby supporting robustness of the outcome measure.

The LP202195 probiotic strain used in the present nested sub-study was selected based on the

findings of Panigrahi *et al.*, which demonstrated that this strain reduced the risk of neonatal

sepsis in India[36]. However, effects of probiotics are species- and strain-specific[37]. To date,

most evidence in support of the role of probiotics in improving iron absorption has stemmed

from research using *L. plantarum* strain 299v, for which potential mechanisms of action include

alteration of intestinal microbiota composition, production of metabolites that may reduce

intestinal pH[21, 22] and increase iron solubility[23]. It is possible that the LP202195 strain does

not substantially affect iron absorption, whereas findings may have differed with use of

alternative strains (such as 299v). In the present trial, LP202195 stool abundance (cells per µg

DNA or per g stool) was greater in the intervention arms (versus placebo) between ~14 and 60

days of age, but progressively declined in the post-intervention period and did not persist beyond

~2 months, indicating a lack of sustained colonization in this study population[30]. Therefore, a

longer duration of probiotic administration to sustain high abundance may be necessary to

produce measurable effects on iron status to 2 months of age and beyond. It is also possible that

the iron absorption-promoting effects of LP202195 are only realized if it is co-administered with

an exogenous iron source, as has been demonstrated in other studies[18, 20]. Hence, effects may

be negligible during the early postnatal period when infants primarily consume human milk and

their iron status is largely determined by prenatal maternal-fetal transfer, potentially explaining

the null findings in the present study. However, two pediatric studies of lactobacilli intervention,

conducted in comparatively older children, did not show improvements in iron status in the

probiotic group, even when co-administered with extrinsic iron: among a population of pre-

school children in Brazil with a high prevalence of anemia, serum ferritin decreased in response

to a fermented milk beverage fortified with iron amino acid chelate and supplemented with

Lactobacillus acidophilus but increased in children who received only the probiotic [27]; and, in

predominantly iron sufficient 8-14 months old Thai children, there was no effect of synbiotic

intervention with *Limosilactobacillus reuteri* and galactooligosaccharide on fractional iron

absorption in response to single serving of a follow-up formula fortified with isotopically-

labelled ferrous sulfate[28]. The present findings, alongside these two aforementioned studies,

suggest a lack of benefit of lactobacilli-containing probiotics on iron uptake in young children.

However, overall interpretation of any evidence of effect of probiotic/synbiotic administration on

iron uptake and status in this age group is limited by heterogeneity in study designs,

probiotic/synbiotic strains, outcome measurements and iron status prior to intervention.

We also measured serum ferritin at ~2 months of age, whereby the mean serum ferritin

concentration was 191ng/ml with a range of 9.6 to 1219ng/ml, consistent with the range of

values observed among Swedish term-born infants in cord blood (8-1112ng/ml) and at 4 months

of age (6-880ng/ml)[38]. Although fetal iron endowment primarily determines iron stores in

early infancy, iron absorption is tightly regulated. Human milk has low concentrations yet highly

bioavailable dietary iron, but when iron stores are sufficient (reflected by high ferritin),

absorption is downregulated[6], limiting the potential for early probiotic interventions to

meaningfully affect iron status.

An important limitation of quantifying fecal iron concentration is that it is not a direct measure of

iron absorption; furthermore, sample processing (particularly lyophilization and ashing) was

time-consuming and labor-intensive, and therefore the method may not be feasible for large

cohorts or where resources are limited. In the present sub-study of a trial that was not primarily

designed to examine stool iron and iron status, resources were available to analyze only one stool

sample per infant, preventing an examination of stool iron trajectories with age. There were

several other limitations of its application within the LP trial. First, the day-14 timepoint was

selected for primary stool iron content analyses as most infants were expected to have completed

the 7-day IP regimen by 14-days postnatal. However, the low but highly bioavailable iron

content of human milk, as discussed above, likely contributed to the overall low stool iron levels

observed, limiting any effect of the probiotic/synbiotic on either fecal iron or serum ferritin at

such an early age. Data on maternal iron supplementation, maternal iron status, and cord blood

ferritin concentration were not available but may have influenced infant iron stores; however,

given the randomized design of the study, these factors are expected to have been evenly

distributed across intervention groups and therefore we do not expect variation in baseline iron

stores to have biased results of the primary analysis. In addition, the low sample size limited the

inferences in sub-group analyses.

In conclusion, fecal iron quantification by AAS was valid and feasibly implemented in a trial of

neonatal administration of *Lactiplantibacillus plantarum* ATCC 202195. A key advantage of the

assay is that it only requires a relatively small aliquot of stored stool collected for other purposes,

yet it is resource-intensive, does not quantify iron absorption, and may not be more informative

than conventional measures of iron status (e.g., serum ferritin) when examining the effects of a

probiotic/synbiotic intervention. In the present application of the assay in a RCT involving young

infants, we did not find evidence that LP202195, when administered as either a probiotic or

synbiotic regimen, influenced early measures of stool iron (2 weeks of age) or iron status (2

months of age). However, further studies are required to understand probiotic attributes in

relation to host iron absorption and iron-gut microbiota interactions, whereby stable isotope

techniques could potentially be considered for a direct reflection of iron absorption.

Acknowledgements

This study was conducted as AZK's doctoral research and therefore was reported in the PhD thesis. AZK and DER conceptualized the study; AZK, DER, RR, and AKR designed the study; RR, AKR and SA conducted laboratory analyses; AZK and HQ performed statistical analyses; AZK and LGP wrote the first draft of the paper; AZK, AKR, HQ, LGP, KMOC, SAS, AAM, RH, SA, SS, DER and RR edited and reviewed the paper. All authors have read and approved the final manuscript.

Investigational products were provided by International Flavors & Fragrances Inc. (IFF), but the company was not involved in the study design, implementation, data analysis, manuscript preparation, or publication decision. The authors are thankful to all SEPSiS project investigators and staff for their contributions to the design and implementation of the LP trial.

Ethical Approval

This study was a sub-study of a randomized, placebo-controlled trial involving neonatal oral administration of LP202195, with or without FOS, for 1- or 7-days, which was approved by the ethical review committees at icddr,b (ERC protocol no. PR-20139), the Bangladesh Institute of Child Health, Dhaka Shishu Hospital, the ethical governing body for the Child Health Research Foundation (ERC protocol no. BICH-ERC-02-02-2019), the Directorate General of Drug Administration (DGDA), Bangladesh (DGDA/CTP-04/2016/672), and the Research Ethics Board at The Hospital for Sick Children, Toronto, Canada (REB no. 1000072200). Additionally, ethical approval was also obtained for this sub-study from the ethical review committees at icddr,b (ERC protocol no. PR-21099), and the Research Ethics Board at The Hospital for Sick Children, Toronto, Canada (REB no. 1000078635).

Data Availability

De-identified data, code files, and all additional information required to reanalyze the data

presented in this manuscript have been deposited at Borealis, The Canadian Dataverse

Repository and will be made publicly available as of the date of publication.

https://doi.org/10.5683/SP3/RJUT53

Sources of support

This work was supported by The Bill & Melinda Gates Foundation (INV-007389 and GR-

02268). The funders had no role in the design or implementation of the study, or the analyses,

interpretation of findings, and the decision to publish the results.

Author Disclosures

The authors have no conflicts of interest to disclose.

References

[1]   Burke RM, Leon JS, Suchdev PS. Identification, prevention and treatment of iron
deficiency during the first 1000 days. Nutrients. 2014;6(10):4093-114.

[2]   Beard JL. Why iron deficiency is important in infant development. J Nutr.
2008;138(12):2534-6.

[3]   Pasricha SR, Hayes E, Kalumba K, Biggs BA. Effect of daily iron supplementation on
health in children aged 4-23 months: a systematic review and meta-analysis of randomised
controlled trials. Lancet Glob Health. 2013;1(2):e77-e86.

[4]   Dorea JG. Iron and copper in human milk. Nutrition. 2000;16(3):209-20.

[5]   Baker RD, Greer FR, Committee on Nutrition American Academy of P. Diagnosis and
prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3
years of age). Pediatrics. 2010;126(5):1040-50.

[6]   Gallahan S, Brower S, Wapshott-Stehli H, Santos J, Ho TTB. A Systematic Review of
Isotopically Measured Iron Absorption in Infants and Children Under 2 Years. Nutrients.
2024;16(22).

[7]   World Health Organization. Guideline: Daily iron supplementation in infants and
children. Geneva: World Health Organization. 2016.
https://www.who.int/publications/i/item/9789241549523.

[8]   World Health Organization. Guideline: WHO recommendations on antenatal care for a
positive pregnancy experience. Geneva: World Health Organization. 2016.
https://www.who.int/publications/i/item/9789241549912.

[9]   Moreno-Fernandez J, Ochoa JJ, Latunde-Dada GO, Diaz-Castro J. Iron Deficiency and
Iron Homeostasis in Low Birth Weight Preterm Infants: A Systematic Review. Nutrients.
2019;11(5).

[10]   Armitage AE, Moretti D. The Importance of Iron Status for Young Children in Low- and
Middle-Income Countries: A Narrative Review. Pharmaceuticals (Basel). 2019;12(2).

[11]   Balarajan Y, Ramakrishnan U, Ozaltin E, Shankar AH, Subramanian SV. Anaemia in
low-income and middle-income countries. Lancet (London, England). 2011;378(9809):2123-35.

[12]   Litwin CM, Calderwood SB. Role of iron in regulation of virulence genes. Clin
Microbiol Rev. 1993;6(2):137-49.

[13]   Jaeggi T, Kortman GA, Moretti D, Chassard C, Holding P, Dostal A, et al. Iron
fortification adversely affects the gut microbiome, increases pathogen abundance and induces
intestinal inflammation in Kenyan infants. Gut. 2015;64(5):731-42.

[14] Suchdev P, Jefferds ME, Ota E, Da Silva Lopes K, de Regil L. Home fortification of
foods with multiple micronutrient powders for health and nutrition in children under two years of
age. Cochrane Database of Systematic Reviews. 2020;2.

[15] Sazawal S, Black RE, Ramsan M, Chwaya HM, Stoltzfus RJ, Dutta A, et al. Effects of
routine prophylactic supplementation with iron and folic acid on admission to hospital and
mortality in preschool children in a high malaria transmission setting: community-based,
randomised, placebo-controlled trial. Lancet. 2006;367(9505):133-43.

[16] Soofi S, Cousens S, Iqbal SP, Akhund T, Khan J, Ahmed I, et al. Effect of provision of
daily zinc and iron with several micronutrients on growth and morbidity among young children
in Pakistan: a cluster-randomised trial. Lancet. 2013;382(9886):29-40.

[17] Zimmermann MB, Chassard C, Rohner F, N'Goran E K, Nindjin C, Dostal A, et al. The
effects of iron fortification on the gut microbiota in African children: a randomized controlled
trial in Cote d'Ivoire. Am J Clin Nutr. 2010;92(6):1406-15.

[18] Vonderheid SC, Tussing-Humphreys L, Park C, Pauls H, OjiNjideka Hemphill N,
LaBomascus B, et al. A Systematic Review and Meta-Analysis on the Effects of Probiotic
Species on Iron Absorption and Iron Status. Nutrients. 2019;11(12).

[19] Rusu IG, Suharoschi R, Vodnar DC, Pop CR, Socaci SA, Vulturar R, et al. Iron
Supplementation Influence on the Gut Microbiota and Probiotic Intake Effect in Iron Deficiency-
A Literature-Based Review. Nutrients. 2020;12(7).

[20] Zakrzewska Z, Zawartka A, Schab M, Martyniak A, Skoczeń S, Tomasik PJ, et al.
Prebiotics, Probiotics, and Postbiotics in the Prevention and Treatment of Anemia.
Microorganisms. 2022;10(7):1330.

[21] Chandrasekaran P, Weiskirchen S, Weiskirchen R. Effects of Probiotics on Gut
Microbiota: An Overview. Int J Mol Sci. 2024;25(11).

[22] Markowiak-Kopeć P, Śliżewska K. The Effect of Probiotics on the Production of Short-
Chain Fatty Acids by Human Intestinal Microbiome. Nutrients. 2020;12(4).

[23] González A, Gálvez N, Martín J, Reyes F, Pérez-Victoria I, Dominguez-Vera JM.
Identification of the key excreted molecule by Lactobacillus fermentum related to host iron
absorption. Food Chem. 2017;228:374-80.

[24] Skrypnik K, Bogdanski P, Schmidt M, Suliburska J. The Effect of Multispecies Probiotic
Supplementation on Iron Status in Rats. Biol Trace Elem Res. 2019;192(2):234-43.

[25] Hoppe M, Onning G, Berggren A, Hulthen L. Probiotic strain Lactobacillus plantarum
299v increases iron absorption from an iron-supplemented fruit drink: a double-isotope cross-
over single-blind study in women of reproductive age. Br J Nutr. 2015;114(8):1195-202.

[26]   Hoppe M, Onning G, Hulthen L. Freeze-dried Lactobacillus plantarum 299v increases
iron absorption in young females-Double isotope sequential single-blind studies in menstruating
women. PLoS One. 2017;12(12):e0189141.

[27]   Silva MR, Dias G, Ferreira CL, Franceschini SC, Costa NM. Growth of preschool
children was improved when fed an iron-fortified fermented milk beverage supplemented with
Lactobacillus acidophilus. Nutr Res. 2008;28(4):226-32.

[28]   Scheuchzer P, Sinawat S, Donzé AS, Zeder C, Sabatier M, Garcia-Garcera M, et al. Iron
Absorption from an Iron-Fortified Follow-Up Formula with and without the Addition of a
Synbiotic or a Human-Identical Milk Oligosaccharide: A Randomized Crossover Stable Isotope
Study in Young Thai Children. J Nutr. 2024;154(10):2988-98.

[29]   Khan AZ, Badar S, O'Callaghan KM, Zlotkin S, Roth DE. Fecal Iron Measurement in
Studies of the Human Intestinal Microbiome. Curr Dev Nutr. 2022;6(10):nzac143.

[30]   Pell Lisa G, Qamar H, Bassani Diego G, Heasley C, Funk C, Chen C-Y, et al. Neonatal
administration of Lactiplantibacillus plantarum ATCC 202195 with or without
fructooligosaccharide in Bangladesh: a placebo-controlled randomized trial. mSphere.
2025;0(0):e01032-24.

[31]   Freitas AC, Li G, Shawon J, Qamar H, Pell LG, Kabir M, et al. Abundance of
Bifidobacterium species in the infant gut microbiota and associations with maternal-infant
characteristics in Dhaka, Bangladesh. mSphere. 2025;10(10):e0031425.

[32]   Pizarro F, Amar M, Stekel A. Determination of iron in stools as a method to monitor
consumption of iron-fortified products in infants. Am J Clin Nutr. 1987;45(2):484-7.

[33]   Fairweather-Tait SJ, Balmer SE, Scott PH, Minski MJ. Lactoferrin and iron absorption in
newborn infants. Pediatr Res. 1987;22(6):651-4.

[34]   Stoffel NU, Zeder C, Zimmermann MB. Assessing Human Iron Kinetics Using Stable
Iron Isotopic Techniques. Clin Pharmacokinet. 2024;63(10):1389-405.

[35]   Yilmaz B, Li H. Gut Microbiota and Iron: The Crucial Actors in Health and Disease.
Pharmaceuticals (Basel). 2018;11(4).

[36]   Panigrahi P, Parida S, Nanda NC, Satpathy R, Pradhan L, Chandel DS, et al. A
randomized synbiotic trial to prevent sepsis among infants in rural India. Nature.
2017;548(7668):407-12.

[37]   McFarland LV, Evans CT, Goldstein EJC. Strain-Specificity and Disease-Specificity of
Probiotic Efficacy: A Systematic Review and Meta-Analysis. Front Med (Lausanne).
2018;5:124.

[38]   Larsson SM, Hillarp A, Hellström-Westas L, Domellöf M, Lundahl T, Andersson O.
When age really matters; ferritin reference intervals during infancy revisited. Scandinavian
Journal of Clinical and Laboratory Investigation. 2019;79(8):590-4.

Figure 1: Stool iron concentrations in pooled samples categorized by sex, age, weight status, and breastfeeding pattern. N=32 pools. Each bar represents the measured stool iron concentration in one pooled sample. Pools are grouped by age and weight status, and breastfeeding patterns are distinguished by color. Pools originally designated as "Partial or No BF" are labelled as "mostly Partial BF" and "No BF" pools are labelled as "Mostly EBF + predominant BF" due to misclassification of the feeding status of some samples at the time the pools were generated (See Section C in Supplementary Material for further details).

Figure 2: Study CONSORT Flow Diagram

Figure 3. Stool iron concentration (mg Fe/100g dried stool), by intervention group (panel A) and feeding pattern as 4 categories (panel B) or 2 categories (panel C). (n=307 samples, one sample per infant). The grey boxplot represents the interquartile range, individual data points are shown as grey circles, and red circle denotes median. Y-axis shown as log scale. Differences in stool iron (natural log-transformed) across intervention groups (Panel A) or feeding patterns (Panel C) were estimated using linear regression model; a Wald test was conducted as a global test of any significant differences between any group and reference (Panel A: p-value = 0.2688 [intervention group, placebo as reference]; Panel C: p-value: 0.0286 [2 category feeding pattern, exclusively breastfed as reference]).

Figure 4. Serum **ferritin concentrations (ng/mL), by intervention group.** (n=251 samples, one sample per infant). The grey boxplot represents the interquartile range, individual data points are shown as grey circles, and red circle denotes median. Y-axis shown as log scale. Differences in ferritin (natural log-transformed) across intervention groups were estimated using linear regression model; a Wald test was conducted as a global test of any significant differences between any IP group and placebo (p-value = 0.9037).